Therapeutic Potential of Alpha-1 Antitrypsin in Type 1 and Type 2 Diabetes Mellitus. Review uri icon

Overview

abstract

  • Alpha-1 antitrypsin (AAT) has established anti-inflammatory and immunomodulatory effects in chronic obstructive pulmonary disease but there is increasing evidence of its role in other inflammatory and immune-mediated conditions, like diabetes mellitus (DM). AAT activity is altered in both developing and established type 1 diabetes mellitus (T1DM) as well in established type 2 DM (T2DM). Augmentation therapy with AAT appears to favorably impact T1DM development in mice models and to affect β-cell function and inflammation in humans with T1DM. The role of AAT in T2DM is less clear, but AAT activity appears to be reduced in T2DM. This article reviews these associations and emerging therapeutic strategies using AAT to treat DM.

publication date

  • April 20, 2021

Research

keywords

  • Diabetes Mellitus, Type 1
  • Diabetes Mellitus, Type 2
  • alpha 1-Antitrypsin Deficiency

Identity

PubMed Central ID

  • PMC8073794

Scopus Document Identifier

  • 85105120932

Digital Object Identifier (DOI)

  • 10.3390/medicina57040397

PubMed ID

  • 33923873

Additional Document Info

volume

  • 57

issue

  • 4